Regeneron Pharmaceuticals Inc (REGN NASDAQ) stock market data APIs
$781.0635
1.18(0.2%)
as of December 26, 2025
Try our APIs with
free plan!
Regeneron Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies; and Tessera Therapeutics, Inc. to develop and commercialize TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Prev. Close
781.0635
Open
781.7537
High
787.8506
Low
780.5404
52 wk Range
475.1718-792.77
Market Cap
83 197 M
P/E Ratio
18.8333
Shares Outstanding
103 M
Revenue
14 248 M
EPS
11.83
Dividends (Yield)
0.0034
Beta
0.368
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Regeneron Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Regeneron Pharmaceuticals Inc data using free add-ons & libraries
Get Regeneron Pharmaceuticals Inc Fundamental Data
Regeneron Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 14 248 M
- EBITDA: 4 348 M
- Earnings Per Share: 41
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 9.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Regeneron Pharmaceuticals Inc News
New
Notable healthcare headlines for the week: J&J, Pfizer, and Novo Nordisk in focus
U.S. stocks snapped a five-day win streak on Friday, amid small moves and low trading volume post the Christmas holiday. The blue-chip Dow Jones Industrial Average slipped -0.04% to 48,710.97 points,...
Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 13 Best Debt Free Dividend Stocks to Buy Now.Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN) On December 12, Morgan ...
Does Regeneron Still Offer Value After Strong Five Year Share Price Gains?
If you are wondering whether Regeneron Pharmaceuticals at around $779 a share is still worth buying, you are not alone. This article is all about what that price actually implies about value. The stoc...
Sanofi And Regeneron's Dupixent Wins Japan Nod For Pediatric Asthma
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) yesterday announced that Japan's Ministry of Health, Labor and Welfare has approved Dupixent for children aged 6 to 11 years with se...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
